1. Home
  2. TRDA vs ELLO Comparison

TRDA vs ELLO Comparison

Compare TRDA & ELLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

N/A

Current Price

$4.65

Market Cap

275.3M

Sector

Health Care

ML Signal

N/A

ELLO

Ellomay Capital Ltd (Israel)

SELL

Current Price

$17.91

Market Cap

255.4M

Sector

Utilities

ML Signal

SELL

Company Overview

Basic Information
Metric
TRDA
ELLO
Founded
2016
1987
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Electric Utilities: Central
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
275.3M
255.4M
IPO Year
2021
1998

Fundamental Metrics

Financial Performance
Metric
TRDA
ELLO
Price
$4.65
$17.91
Analyst Decision
Strong Buy
Analyst Count
8
0
Target Price
★ $17.75
N/A
AVG Volume (30 Days)
★ 449.9K
2.1K
Earning Date
11-05-2026
12-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $25,421,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$361.69
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$4.11
$17.00
52 Week High
$16.45
$30.34

Technical Indicators

Market Signals
Indicator
TRDA
ELLO
Relative Strength Index (RSI) 44.20 41.27
Support Level $4.18 $17.54
Resistance Level $5.13 $20.40
Average True Range (ATR) 0.51 0.60
MACD 0.05 -0.27
Stochastic Oscillator 23.15 14.92

Price Performance

Historical Comparison
TRDA
ELLO

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About ELLO Ellomay Capital Ltd (Israel)

Ellomay Capital Ltd is a renewable energy company. It develops and operates renewable energy projects in Europe, the USA, and Israel, employing diverse technologies such as solar power, natural gas, pumped hydro, and waste-to-energy solutions. Geographically, the company operates in segments: Italy; Spain; USA; Netherland and Israel. It derives maximum revenue from Spain.

Share on Social Networks: